Cohort Studyhigh evidence
Association of GLP-1 receptor agonists with alcohol use disorder-related and substance use disorder-related hospital admissions during treatment and after discontinuation: a Swedish register-based within-individual observational study.
The lancet. Psychiatry·August 1, 2026·PMID 42456704
Why it mattersAlcohol and substance use disorders are prevalent and impactful in patients with metabolic disease, yet pharmacologic options remain limited. These real-world data suggest GLP-1 receptor agonists may reduce serious substance-related events, with implications for medication selection and monitoring after discontinuation.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled